Balance Sheet
Cash Flow Statement
Capital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashDeferred TaxesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Exchange Rate EffectExchange Rate EffectFree Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesNet Cash FlowNet Cash FlowNet IncomeNon-cash ItemsNon-cash ItemsShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Bicycle Therapeutics (BCYC) Depreciation and Depletion (2018 - 2024)

Bicycle Therapeutics' Depreciation and Depletion history spans 7 years, with the latest figure at $1.6 million for Q2 2024.

  • For Q2 2024, Depreciation and Depletion changed 0.0% year-over-year to $1.6 million; the TTM value through Jun 2024 reached $6.6 million, up 10.0%, while the annual FY2023 figure was $6.5 million, 75.68% up from the prior year.
  • Depreciation and Depletion reached $1.6 million in Q2 2024 per BCYC's latest filing, down from $1.7 million in the prior quarter.
  • In the past five years, Depreciation and Depletion ranged from a high of $1.7 million in Q3 2023 to a low of $300000.0 in Q1 2020.
  • Average Depreciation and Depletion over 5 years is $900000.0, with a median of $500000.0 recorded in 2020.
  • Peak YoY movement for Depreciation and Depletion: tumbled 50.0% in 2020, then surged 333.33% in 2022.
  • A 5-year view of Depreciation and Depletion shows it stood at $400000.0 in 2020, then changed by 0.0% to $400000.0 in 2021, then skyrocketed by 275.0% to $1.5 million in 2022, then grew by 6.67% to $1.6 million in 2023, then changed by 0.0% to $1.6 million in 2024.
  • Per Business Quant, the three most recent readings for BCYC's Depreciation and Depletion are $1.6 million (Q2 2024), $1.7 million (Q1 2024), and $1.6 million (Q4 2023).